{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-269383","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2026-06-12T20:05:29+00:00","discovered_at":"2026-06-12T20:07:00.305987+00:00","generated_at":"2026-06-12T20:11:31.585216+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Immunome shareholders elect three Class III directors, ratify auditor, approve say-on-pay","bullets":["James Boylan elected with 70.2M votes for, 22.2M withheld; Sandra Swain and Philip Wagenheim each received over 92M votes for.","Ernst & Young ratified as independent auditor for FY 2026 with 104.1M votes for, 27,134 against.","Advisory vote on executive compensation approved: 90.9M for, 1.4M against, 31K abstentions.","Stockholders preferred annual advisory votes on exec compensation (91.9M for 1-year); company will hold annual votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-269383","json":"https://secwatch.observer/filing/0001193125-26-269383.json","markdown":"https://secwatch.observer/filing/0001193125-26-269383.md","text":"https://secwatch.observer/filing/0001193125-26-269383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526269383/0001193125-26-269383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526269383/imnm-20260609.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T20:11:31.585216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14045023a18f48bfde322e8a5206211591c5eb38","claim":"Immunome Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.","evidence_excerpt":"The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes James Boylan 70,209,570 22,171,996 11,768,578 Sandra Swain, M.D. 92,157,301 224,265 11,768,578 Philip Wagenheim 92,162,632 218,934 11,768,578","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526269383/0001193125-26-269383-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"551b5ef61e8357f4e3333a26b3270a704a87cdbd","claim":"Immunome Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the Audit Committee of the Company’s Board of Directors. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 104,100,900 27,134 22,110 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526269383/0001193125-26-269383-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"9cb010cd50f266d08568311d3edb118a0d4d5668","claim":"Immunome Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-09 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 90,908,436 1,442,116 31,014 11,768,578","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526269383/0001193125-26-269383-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"f7e89e708626d20b0190b7a935f6da949218e176","claim":"Immunome Inc. shareholders approved Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation at the 2026-06-09 meeting.","evidence_excerpt":"The Company’s stockholders indicated, on an advisory basis, their preference for the frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 91,949,591 368,407 41,534 22,034 11,768,578","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526269383/0001193125-26-269383-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}